Latest Insider Transactions at Alumis Inc. (ALMS)
This section provides a real-time view of insider transactions for Alumis Inc. (ALMS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ALUMIS INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ALUMIS INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 05
2025
|
Srinivas Akkaraju |
BUY
Open market or private purchase
|
Indirect |
186,377
+4.91%
|
$1,677,393
$9.9 P/Share
|
|
Dec 04
2025
|
Srinivas Akkaraju |
BUY
Open market or private purchase
|
Indirect |
66,027
+5.77%
|
$528,216
$8.18 P/Share
|
|
Dec 03
2025
|
Srinivas Akkaraju |
BUY
Open market or private purchase
|
Indirect |
100,000
+8.99%
|
$700,000
$7.75 P/Share
|
|
Dec 02
2025
|
Srinivas Akkaraju |
BUY
Open market or private purchase
|
Indirect |
96,000
+9.52%
|
$672,000
$7.55 P/Share
|
|
Dec 01
2025
|
Srinivas Akkaraju |
BUY
Open market or private purchase
|
Indirect |
86,350
+9.56%
|
$604,450
$7.46 P/Share
|
|
Nov 28
2025
|
Srinivas Akkaraju |
BUY
Open market or private purchase
|
Indirect |
38,702
+5.03%
|
$270,914
$7.64 P/Share
|
|
Nov 26
2025
|
Srinivas Akkaraju |
BUY
Open market or private purchase
|
Indirect |
48,537
+6.56%
|
$339,759
$7.64 P/Share
|
|
Nov 21
2025
|
Foresite Labs, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
72,212
+2.69%
|
$505,484
$7.38 P/Share
|
|
Nov 21
2025
|
James B. Tananbaum Director |
BUY
Open market or private purchase
|
Indirect |
72,212
+2.69%
|
$505,484
$7.38 P/Share
|
|
Nov 21
2025
|
Foresite Capital Management Vi LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
72,212
+2.69%
|
$505,484
$7.38 P/Share
|
|
Nov 20
2025
|
Srinivas Akkaraju |
BUY
Open market or private purchase
|
Indirect |
125,743
+16.35%
|
$880,201
$7.2 P/Share
|
|
Nov 19
2025
|
James B. Tananbaum Director |
BUY
Open market or private purchase
|
Indirect |
190,500
+6.97%
|
$1,143,000
$6.56 P/Share
|
|
Nov 19
2025
|
Foresite Capital Management Vi LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
190,500
+6.97%
|
$1,143,000
$6.56 P/Share
|
|
Nov 19
2025
|
Foresite Labs, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
190,500
+6.97%
|
$1,143,000
$6.56 P/Share
|
|
Nov 19
2025
|
Srinivas Akkaraju |
BUY
Open market or private purchase
|
Indirect |
137,772
+21.02%
|
$826,632
$6.56 P/Share
|
|
Nov 18
2025
|
James B. Tananbaum Director |
BUY
Open market or private purchase
|
Indirect |
117,374
+4.75%
|
$704,244
$6.19 P/Share
|
|
Nov 18
2025
|
Foresite Capital Management Vi LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
117,374
+4.75%
|
$704,244
$6.19 P/Share
|
|
Nov 18
2025
|
Foresite Labs, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
117,374
+4.75%
|
$704,244
$6.19 P/Share
|
|
Nov 18
2025
|
Srinivas Akkaraju |
BUY
Open market or private purchase
|
Indirect |
102,652
+21.28%
|
$615,912
$6.05 P/Share
|
|
Nov 17
2025
|
James B. Tananbaum Director |
BUY
Open market or private purchase
|
Indirect |
200,000
+4.32%
|
$1,000,000
$5.6 P/Share
|
|
Nov 17
2025
|
Foresite Capital Management Vi LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
200,000
+4.32%
|
$1,000,000
$5.6 P/Share
|
|
Nov 17
2025
|
Foresite Labs, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
200,000
+4.32%
|
$1,000,000
$5.6 P/Share
|
|
Nov 17
2025
|
Srinivas Akkaraju |
BUY
Open market or private purchase
|
Indirect |
914
+0.33%
|
$4,570
$5.51 P/Share
|
|
Nov 13
2025
|
Srinivas Akkaraju |
BUY
Open market or private purchase
|
Indirect |
276,179
+50.0%
|
$1,380,895
$5.25 P/Share
|
|
Jul 29
2025
|
Mark Christopher Bradley Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,750
+35.44%
|
-
|
|
Jul 29
2025
|
Jorn Drappa Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,450
+47.22%
|
-
|
|
Jul 29
2025
|
David M Goldstein Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,000
+48.12%
|
-
|
|
Jul 29
2025
|
Roy C. Hardiman Chief Business & Strategy Ofcr |
BUY
Grant, award, or other acquisition
|
Direct |
28,000
+11.95%
|
-
|
|
Jul 29
2025
|
John R. Schroer Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,000
+50.0%
|
-
|
|
Jul 29
2025
|
Derrick Richardson SVP, People and Culture |
BUY
Grant, award, or other acquisition
|
Direct |
42,800
+50.0%
|
-
|
|
Jul 29
2025
|
Sanam Pangali Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+47.37%
|
-
|
|
May 21
2025
|
Srinivas Akkaraju |
BUY
Grant, award, or other acquisition
|
Indirect |
1,214,582
+20.19%
|
-
|
|
May 21
2025
|
Ayur Maya Capital Management Company, LP Director |
BUY
Grant, award, or other acquisition
|
Indirect |
4,493,741
+22.89%
|
-
|
|
May 21
2025
|
Patrick Machado |
BUY
Grant, award, or other acquisition
|
Indirect |
7,064
+50.0%
|
-
|
|
May 06
2025
|
Foresite Capital Management Vi LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
20,000
+0.47%
|
$80,000
$4.34 P/Share
|
|
May 06
2025
|
Foresite Labs, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
20,000
+0.47%
|
$80,000
$4.34 P/Share
|
|
May 06
2025
|
James B. Tananbaum Director |
BUY
Open market or private purchase
|
Indirect |
20,000
+0.47%
|
$80,000
$4.34 P/Share
|
|
May 05
2025
|
Srinivas Akkaraju |
BUY
Open market or private purchase
|
Indirect |
160,370
+2.17%
|
$641,480
$4.93 P/Share
|
|
May 02
2025
|
Foresite Capital Management Vi LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
25,000
+0.59%
|
$100,000
$4.62 P/Share
|
|
May 02
2025
|
Foresite Labs, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
25,000
+0.59%
|
$100,000
$4.62 P/Share
|
|
May 02
2025
|
James B. Tananbaum Director |
BUY
Open market or private purchase
|
Indirect |
25,000
+0.59%
|
$100,000
$4.62 P/Share
|
|
May 02
2025
|
Srinivas Akkaraju |
BUY
Open market or private purchase
|
Indirect |
159,920
+4.46%
|
$639,680
$4.55 P/Share
|
|
Apr 02
2025
|
Alan Colowick |
BUY
Open market or private purchase
|
Indirect |
2,300
+11.11%
|
$16,100
$7.49 P/Share
|
|
Apr 01
2025
|
Martin Babler President, CEO and Chairman |
BUY
Open market or private purchase
|
Indirect |
15,650
+12.82%
|
$93,900
$6.44 P/Share
|
|
Apr 01
2025
|
Alan Colowick |
BUY
Open market or private purchase
|
Indirect |
16,104
+50.0%
|
$96,624
$6.97 P/Share
|
|
Jul 01
2024
|
James B. Tananbaum Director |
BUY
Open market or private purchase
|
Indirect |
2,500,000
+19.77%
|
$40,000,000
$16.0 P/Share
|
|
Jul 01
2024
|
James B. Tananbaum Director |
BUY
Conversion of derivative security
|
Indirect |
11,476,484
+32.61%
|
-
|
|
Jul 01
2024
|
Foresite Capital Management V, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
2,500,000
+19.77%
|
$40,000,000
$16.0 P/Share
|
|
Jul 01
2024
|
Foresite Capital Management V, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
11,476,484
+32.61%
|
-
|
|
Jul 01
2024
|
Foresite Labs, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
2,500,000
+19.77%
|
$40,000,000
$16.0 P/Share
|